ArticleScientific reports2023
Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Predicting radioiodine therapy response in advanced and recurrent thyroid cancer.Endocrine-related cancer · 2026Article
- The Association of Interstitial Fibrosis and Ki67 Marker Expression in Papillary Thyroid Carcinoma with Histopathological Findings and Prognosis of Total Thyroidectomy.Journal of clinical medicine · 2026Article
- BRAF V600E/TERT Promoter Co-Mutation Is Associated with Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Translational Molecular Biomarker Study.Biomedicines · 2026Article
- Prognostic factors evaluated in differentiated thyroid carcinomas.Endocrine connections · 2026Review
- The diagnostic efficacy of serum galectin-3 and other markers in papillary thyroid carcinoma.Gland surgery · 2025Article
- Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.Journal of neuro-oncology · 2025Article
- BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression.Endocrine connections · 2025Article
- Gene Expression Analysis of Papillary Thyroid Carcinoma With Lymph Node Metastasis and Radioiodine Refractivity.Cureus · 2025Article
- Prognostic value of lactate dehydrogenase to albumin ratio in first-line chemoimmunotherapy for locally advanced or metastatic non-small cell lung cancer.Translational cancer research · 2025Article
- Environmental Exposure to Bisphenol A Enhances Invasiveness in Papillary Thyroid Cancer.International journal of molecular sciences · 2025Article
- Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer.Frontiers in oncology · 2025Article
- Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings.European thyroid journal · 2024Review
- Clinical and Paraclinical Considerations Regarding ki67's Role in the Management of Differentiated Thyroid Carcinoma-A Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- KI-67 as a predictive indicator of papillary thyroid cancer in Iraqi patients.Problemy endokrinologii · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical significance of thyroglobulin (Tg) expression in papillary thyroid cancer (PTC) has not been systematically explored in relation to the Ki-67 index, lymph node ratio (LNR), or other conventional prognostic predictors. In this retrospective study of 327 patients with PTC, we investigated the immunohistochemical expression of Tg in both primary tumors and their matching lymph node metastases in relation to the Ki-67 index, LNR, and clinical data. Tumoral Tg immunoreactivity was inversely correlated to the Ki-67 index and tumor recurrence. The Ki-67 index was higher in lymph node metastases (mean 4%) than in the primary tumors (mean 3%). Reduced Tg expression, estimated as 0-25% Tg positive tumor cells, was more common in lymph node metastases compared to primary tumors. In addition to advanced metastatic burden (defined as N1b stage and LNR ≥ 21%), low Tg expression (0-25% positive tumor cells) in lymph node metastases had a significant prognostic impact with shorter recurrence-free survival. These findings support the potential value of histopathological assessment of Tg expression and Ki-67 index in lymph node metastases as complementary predictors to anticipate the prognosis of PTC patients better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.